Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BDA MDI · 1 trial · 1 indication
The effect of BDA MDI compared with AS MDI, both administered as needed, on the AAER in participants with asthma will be evaluated.
| Arm | Type | Description |
|---|---|---|
| Budesonide/albuterol metered -dose inhaler (BDA MDI) | EXPERIMENTAL | Participants will receive BDA MDI 160/180 μg (given as 2 puffs of 80/90 μg) as needed. |
| Albuterol sulfate metered-dose inhaler (AS MDI) | ACTIVE_COMPARATOR | Participants will receive AS MDI 180 μg (given as 2 puffs of 90 μg) as needed. |
| Name | Type | Description |
|---|---|---|
| BDA MDI | COMBINATION_PRODUCT | Participants will receive oral inhalation of BDA MDI 160/180 μg taken as 2 puffs of 80/90 μg as needed. |
| AS MDI | COMBINATION_PRODUCT | Participants will receive oral inhalation of AS MDI 180 μg taken as 2 puffs of 90 μg as needed. |
Inclusion Criteria: * Confirmed clinical diagnosis of asthma at least 12 months. * Receiving one of the following scheduled asthma maintenance therapies for at least 3 months with stable dosing for at least the last one month 1. Low-to-high-dose Inhaled corticosteroid(s) (ICS) 2. Low-to-high-d...
BDA MDI is an investigational small molecule being developed for the treatment of asthma. It is currently in Phase 3 clinical development and is being studied in adolescents aged 12 to under 18 years with asthma. The drug is administered as needed and is being evaluated for its efficacy and safety in this patient population.
BDA MDI is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is currently conducting a Phase 3 clinical trial to evaluate the drug's efficacy and safety in adolescent patients with asthma.
BDA MDI is currently in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 3 trial is actively recruiting participants to assess the drug's efficacy and safety in adolescents with asthma.
BDA MDI is being studied in a Phase 3 clinical trial registered as NCT06307665. This randomized, double-blind, active-controlled study is evaluating the efficacy and safety of BDA MDI compared with PT007 administered as needed in participants aged 12 to under 18 years with asthma. The trial is recruiting 440 participants across the United States, China, Mexico, and South Africa.
BDA MDI is a small molecule developed for the treatment of asthma. The specific molecular target of BDA MDI has not been disclosed in the available information. The drug is administered as needed and is being evaluated in a Phase 3 clinical trial for its efficacy and safety in adolescent patients with asthma.